AI Analysis
Log in to generate an AI summary for this stock.
Log in to generate a MOAT report for this stock.
Log in to generate an earnings report for this stock.
Log in to generate an operating leverage report for this stock.
Log in to generate a management report for this stock.
Log in to generate a valuation report for this stock.
The Precision Peptide Company Inc
Video analysis: PNGAF
All videosNo video analysis for this stock yet. Request one from our team.
News: PNGAF
The Precision Peptide Company Announces Grants of RSUs and Stock Options
Vancouver, British Columbia--(Newsfile Corp. - September 4, 2026) - The Precision Peptide Company Inc. (CSE: BPC) (OTCQB: PNGAF) (the "Company") announces that on July 31, 2026, it has authorized the grant of restricted share units (the "RSUs") and incentive stock options (the "Options") pursuant to the Company's omnibus share incentive plan (the "Plan"). The Company has granted 150,000 RSUs and 200,000 Options to a certain consultant of the Company.
The Precision Peptide Company to Showcase Its Needle-Free Recovery Patch and Supplement Range at FitExpo Anaheim
Highlights The Company's supplement range, led by The Recovery Patch, will be available for purchase on site at FitExpo Anaheim, August 29 and 30, 2026 A 15% event discount will be available to attendees on purchases at booth 750, Anaheim Convention Center The Recovery Patch, the Company's needle-free transdermal peptide patch, achieved 95.5% chromatographic purity and a quantified 2.02 mg dose per patch in previously announced independent laboratory testing A key member of the Company's leadership team will speak on the role of peptides in biohacking as part of the Biohack Basics panel on Saturday, August 29 The appearance follows the Company's recent nationwide direct-to-consumer launch and extends its commercial rollout into live retail settings Vancouver, British Columbia--(Newsfile Corp. - August 25, 2026) - The Precision Peptide Company (CSE: BPC) (OTCQB: PNGAF) (the "Company" or "Precision Peptide"), a publicly traded wellness company focused on advanced peptide formulations and delivery systems, is pleased to announce that it will exhibit and sell its supplement range at FitExpo Anaheim, on August 29 and 30, 2026 at the Anaheim Convention Center ("FitExpo Anaheim"). FitExpo Anaheim is a two-day consumer fitness event featuring competitions, athlete appearances and exhibitor showcases, drawing an audience of fitness, strength and wellness enthusiasts from across Southern California.
The Precision Peptide Company Inc. Announces Development of Needle-Free Tirzepatide Transdermal Patch
Vancouver, British Columbia--(Newsfile Corp. - August 19, 2026) - The Precision Peptide Company (CSE: BPC) (OTCQB: PNGAF) (the "Company" or
The Precision Peptide Company Completes Migration of Amino Innovations Online Store and Customer Base to Company Website
Vancouver, British Columbia--(Newsfile Corp. - August 7, 2026) - The Precision Peptide Company (CSE: BPC) (OTCQB: PNGAF) (the "Company" or "BPC"), a publicly traded wellness company focused on advanced peptide formulations and delivery systems, today announced that it has completed the migration of the Amino Innovations online supplement store www.aminoinnovations.com (the "Amino Innovations Store"), including its product catalogue and existing customer base, onto the Company's e-commerce platform at www.precisionpeptidecompany.com. Following the migration, sales through the legacy Amino Innovations Store have now ceased, and all traffic is directed to the Company platform.
The Precision Peptide Company Targets Launch of the Peptide Pen, Expanding Its U.S.-Made Product Platform
Highlights The Company introduces expected launch of the Peptide Pen, its second commercial product, marking a significant expansion beyond transdermal patches into precision injection delivery Designed, manufactured, and tested in the United States in a cGMP-certified facility using medical-grade materials Features a 5mL dosing configuration, a first for a combined pen-and-vial peptide device, offering significantly more capacity than the standard 3mL cartridges commonly available Interchangeable cartridge system allows customers to switch between different peptide protocols using a single device, reducing cost and complexity Commercial release targeted for August 2026 Vancouver, British Columbia--(Newsfile Corp. - August 4, 2026) - The Precision Peptide Company (CSE: BPC) (OTCQB: PNGAF) (the "Company" or "BPC"), a publicly traded wellness company focused on advanced peptide formulations and delivery systems, today announces the introduction of the Peptide Pen (the "Peptide Pen"), the Company's second commercial product. The launch of the Peptide Pen is expected to represent a significant expansion of the Company's product offering, building on its BPC-157 transdermal patch with a new precision injection delivery system.
The Precision Peptide Company Opens Nationwide Retail Sales Days After FDA Panel Backs Six of Seven Peptides Under Review
Highlights Seven products are now in stock and available to purchase at precisionpeptidecompany.com: BPC, KPV, Ageless, Chill, Blue, Hair and The Recovery Patch The Recovery Patch is the Company's first transdermal peptide product available at retail, providing a needle-free format that requires no mixing, no measuring and no cold storage All 50 U.S. states can order through the platform LegitScript Healthcare Merchant Certification supports compliance, consumer-safety, payment-processing and advertising standards GLP-1, Sermorelin and NAD+ protocols are listed on the platform as coming soon, supported by the Company's previously announced 503A compounding agreement and telehealth infrastructure On July 23 and 24, 2026, the FDA's Pharmacy Compounding Advisory Committee voted in favour of six of the seven peptides it reviewed. Four of those six are used in the Company's existing formulations.
The Precision Peptide Company Advances First-to-Market Thymosin Alpha-1 Patch for Immune Support
Highlights Q3/Q4 2026 is the targeted completion period for testing of The Precision Peptide Company's Thymosin Alpha-1 transdermal patch 2025 research continues to evaluate Thymosin Alpha-1 for immune regulation and inflammation, supporting its ongoing relevance within the peptide and immune-health landscape¹ The patch is being developed to bring Thymosin Alpha-1 into a portable, needle-free format without mixing or cold storage Based on its review of currently publicly available products, The Precision Peptide Company believes the product could be among the first commercially available Thymosin Alpha-1 transdermal patches Testing will evaluate formulation stability and performance within the transdermal patch format The program expands the transdermal portfolio into the immune-support category Vancouver, British Columbia--(Newsfile Corp. - July 28, 2026) - The Precision Peptide Company (CSE: BPC) (OTCQB: PNGAF) (the "Company" or "BPC"), a publicly traded wellness company focused on advanced peptide formulations and delivery systems, today announced that testing is underway for its Thymosin Alpha-1 transdermal patch. Testing is focused on formulation stability and performance within the patch format and is targeted for completion in Q3/Q4 2026.
The Precision Peptide Company Applauds FDA Advisory Committee Vote on Expanded Pathway for BPC-157 and KPV
On July 23, 2026, the FDA's Pharmacy Compounding Advisory Committee voted 8-6 (one abstention) to recommend BPC-157 for inclusion on the Section 503A Bulks List. BPC-157 was the first of seven peptides considered at the July 23-24 meeting.
Similar companies
-
Reliv' International, Inc.
RELV
·
Other OTC
Compare
-
Psyched Wellness Ltd
PSYCF
·
Other OTC
Compare
-
Tofutti Brands Inc.
TOFB
·
Other OTC
Compare
-
Glucose Health, Inc.
GLUC
·
Other OTC
Compare
-
Century Global Commodities Corporation
CEUMF
·
Other OTC
Compare
-
Flow Beverage Corp.
FLWBF
·
Other OTC
Compare